The purpose of role is to provide expertise in the development of methods for the characterisation, analysis and development of their next generation of therapies. You will report directly to the Associate Director and will be responsible for the development of novel methods as well a the optimisation of existing processes. For this role you will need to use your creativity and innovative thinking to develop processes.
This Team plays a key role in the transfer of knowledge and insights between the R&D and CMC Team working closely with different sub teams. As this is a more senior role you will have the responsibility for input into the design, execution and delivery of experimental programmes.
The core responsibilities are:
- Design and optimise methods for product research and development
- Develop, run and optimise cell based assays and flow cytometry experiments.
- Provide scientific expertise to develop assays as well as troubleshooting and optimisation.
- Analyse data to provide input into research programmes and present data to the wider team.
- Work collaboratively with other teams and groups.
- Oversee the transfer of methods internally.
- Mentor more junior team members
- PhD in a relevant area such as immunology.
- Good understanding of T Cell biology
- Demonstrable experience in the development and optmisation of assays.
- Experienced in the development and running of multi parameter Flow Cytometry.
- Experience at working with software – e.g. Flow Jo or Prism
- Experience of mammalian and primary cell culture using aseptic techniques.
The company have developed unique T – Cell technologies that are innovative and life changing for patients that suffer from autoimmune and inflammatory diseases. As well as having the potential to prevent the rejection of new organs following transplant. This technology is based on modular, engineered Tregs.
They are engineering T – Cells ex vivo that suppress the immune system and have the ability to direct the cells to the right area of the body. They are now expanding their operations as their cell therapies progress to clinical trials, develop their pipeline further and develop manufacturing operations for Phase I trials.
As a company they are led by some of the leading minds in their field are driven and committed to the development of therapies that are life changing to patients. With the vision to develop a global biopharmaceutical company that is bringing cell therapies for a range of diseases beyond their current pipeline.